Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford Health Plan (OXHP) -- Ignore unavailable to you. Want to Upgrade?

To: Raptor who wrote (1244)	3/5/1998 5:26:00 PM
From: Johnnie W.	Read Replies (2) \| Respond to of 2068

OXHP will decline in a steady fashion first leveling at 14 then 12 then 10 then to 2. I owned Healthsource when Payton was CEO and wasn't satisfied with him at all. HS declined for year and was finally only sold for its franchise value at @ $22/share. It was a money loser when purchased. IMO, OXHP has less of a franchise value because not only is it a money loser, but its enrolloees are prima donnas who expect top notch treatment (which is very expensive treatment). No buyer in todays market will pay for these prima donnas because they know these prima donnas will only become disatisfied and leave their new HMO. Healthsource was a tight HMO and OXHP is not. Once OXHP current enrollees see their benefits shrinking they will jump ship. This will cause the demise of OXHP. They will receive no new funding to stay afloat!